Galcanezumab: First Global Approval

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study

(2018) Tina Marie Myers Oakes et al.   CEPHALALGIA

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

(2018) Vladimir Skljarevski et al.   JAMA Neurology

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

(2017) David Monteith et al.   Frontiers in Pharmacology

Targeting CGRP: A New Era for Migraine Treatment

(2015) Stephanie Wrobel Goldberg et al.   CNS DRUGS

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain

(2014) R.J. Benschop et al.   OSTEOARTHRITIS AND CARTILAGE